Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cervera, R
Right arrow Articles by Balasch, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cervera, R
Right arrow Articles by Balasch, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 13, No. 9, 683-687 (2004)
DOI: 10.1191/0961203304lu1092oa

The management of pregnant patients with antiphospholipid syndrome

R Cervera

Department of Autoimmune Diseases, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain, rcervera{at}clinic.ub.es

J Balasch

Institut Clínic of Gynaecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain

Recurrent pregnancy loss is now considered a treatable clinical condition associated with antiphospholipid antibodies. The management of pregnant patients with antiphospholipid syndrome is mainly based on the use of antiaggregant/anticoagulant agents (with aspirin and heparin) to prevent thrombosis in the uteroplacental circulation. Interventions with these drug therapies and monitored pregnancy have increased fetal survival.

Key Words: antiphospholipid antibodies • antiphospholipid syndrome • aspirin • heparin • lupus anticoagulant • pregnancy loss


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
D. A. Garcia, M. A. Khamashta, and M. A. Crowther
How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
Blood, November 1, 2007; 110(9): 3122 - 3127.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J. A Gomez-Puerta, R. Cervera, G. Espinosa, R. A Asherson, M. Garcia-Carrasco, I. P da Costa, D. C O Andrade, E. F Borba, A. Makatsaria, S. Bucciarelli, et al.
Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases
Ann Rheum Dis, June 1, 2007; 66(6): 740 - 746.
[Abstract] [Full Text] [PDF]